IHC validation was then performed in an independent cohort of Gleason score 6 and 7 prostate cancer tissues and again there was a significant association between early disease recurrence and low methyl-PP2A-C scores in the Gleason score 7 group indicating that at this disease stage the loss of PP2A-C methylation might indeed be linked to the progression to metastatic disease and treatment resistance (Supplementary Fig. 2d–f). Here, PPP2CA is linked to prostate cancer.